- $139.35bn
- $188.22bn
- $63.63bn
- 98
- 87
- 81
- 99
Annual balance sheet for Pfizer, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 12,221 | 31,069 | 22,732 | 12,690 | 20,477 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 7,930 | 11,479 | 14,529 | 15,155 | 14,777 |
| Total Inventory | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 35,067 | 59,693 | 51,259 | 43,333 | 50,358 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 15,293 | 17,721 | 19,276 | 21,864 | 20,682 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 154,229 | 181,476 | 197,205 | 226,501 | 213,396 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 25,920 | 42,671 | 42,138 | 47,794 | 42,995 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 90,991 | 104,276 | 101,545 | 137,487 | 125,193 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 63,238 | 77,200 | 95,660 | 89,014 | 88,203 |
| Total Liabilities & Shareholders' Equity | 154,229 | 181,476 | 197,205 | 226,501 | 213,396 |
| Total Common Shares Outstanding | |||||
| Total Preferred Shares Outstanding |